INTRODUCTION: The ubiquity and hazards posed by abnormal body composition and metabolic parameters in the bipolar population are a priority research and clinical issue. Herein, we summarize and synthesize international studies describing the rate of US National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III])- and International Diabetes Federation (IDF)-defined metabolic syndrome and its criterion components in individuals with bipolar disorder. METHODS: We conducted a PubMed search of all English-language articles published between January 2005 and July 2009 with the following search terms: metabolic syndrome and bipolar disorder, mania and manic-depression. Articles selected for review were based on adequacy of sample size, the use of standardized experimental procedures, validated assessment measures, and overall manuscript quality. RESULTS: The rate of metabolic syndrome in individuals with bipolar disorder is increased relative to the general population. Disparate estimates are reported ranging from comparability to approximately twofold greater than the general population. The increased hazard for metabolic syndrome amongst bipolar individuals is now documented in twelve countries from Europe, Australia, Asia, North and South America. The co-occurrence of metabolic syndrome in the bipolar population is associated with a more complex illness presentation, less favourable response to treatment, and adverse course and outcome. The association between metabolic syndrome and bipolar disorder is mediated/moderated by both iatrogenic and non-iatrogenic factors. DISCUSSION: The increased hazard for metabolic syndrome in bipolar populations is due to the clustering of traditional (and emerging) risk factors as well as iatrogenic and health systems factors. Extant data support recommendations for prioritizing, surveillance, prevention, diagnosis and management of metabolic syndrome as routine care of the bipolar patient.
INTRODUCTION: The ubiquity and hazards posed by abnormal body composition and metabolic parameters in the bipolar population are a priority research and clinical issue. Herein, we summarize and synthesize international studies describing the rate of US National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III [ATP III])- and International Diabetes Federation (IDF)-defined metabolic syndrome and its criterion components in individuals with bipolar disorder. METHODS: We conducted a PubMed search of all English-language articles published between January 2005 and July 2009 with the following search terms: metabolic syndrome and bipolar disorder, mania and manic-depression. Articles selected for review were based on adequacy of sample size, the use of standardized experimental procedures, validated assessment measures, and overall manuscript quality. RESULTS: The rate of metabolic syndrome in individuals with bipolar disorder is increased relative to the general population. Disparate estimates are reported ranging from comparability to approximately twofold greater than the general population. The increased hazard for metabolic syndrome amongst bipolar individuals is now documented in twelve countries from Europe, Australia, Asia, North and South America. The co-occurrence of metabolic syndrome in the bipolar population is associated with a more complex illness presentation, less favourable response to treatment, and adverse course and outcome. The association between metabolic syndrome and bipolar disorder is mediated/moderated by both iatrogenic and non-iatrogenic factors. DISCUSSION: The increased hazard for metabolic syndrome in bipolar populations is due to the clustering of traditional (and emerging) risk factors as well as iatrogenic and health systems factors. Extant data support recommendations for prioritizing, surveillance, prevention, diagnosis and management of metabolic syndrome as routine care of the bipolar patient.
Authors: Christine Li; Boris Birmaher; Brian Rooks; Mary Kay Gill; Heather Hower; David A Axelson; Daniel P Dickstein; Tina R Goldstein; Fangzi Liao; Shirley Yen; Jeffrey Hunt; Satish Iyengar; Neal D Ryan; Michael A Strober; Martin B Keller; Benjamin I Goldstein Journal: J Clin Psychiatry Date: 2019-07-30 Impact factor: 4.384
Authors: Steven E Arnold; Irwin Lucki; Bethany R Brookshire; Gregory C Carlson; Caroline A Browne; Hala Kazi; Sookhee Bang; Bo-Ran Choi; Yong Chen; Mary F McMullen; Sangwon F Kim Journal: Neurobiol Dis Date: 2014-03-29 Impact factor: 5.996
Authors: Michael J Bly; Stephan F Taylor; Gregory Dalack; Rodica Pop-Busui; Kyle J Burghardt; Simon J Evans; Melvin I McInnis; Tyler B Grove; Robert D Brook; Sebastian K Zöllner; Vicki L Ellingrod Journal: Bipolar Disord Date: 2013-12-13 Impact factor: 6.744
Authors: A John Camm; Onur N Karayal; Herbert Meltzer; Sheela Kolluri; Cedric O'Gorman; Jeffrey Miceli; Thomas Tensfeldt; John M Kane Journal: CNS Drugs Date: 2012-04-01 Impact factor: 5.749
Authors: Roger S McIntyre; Susan L McElroy; James M Eudicone; Robert A Forbes; Berit X Carlson; Ross A Baker Journal: Prim Care Companion CNS Disord Date: 2011
Authors: David E Kemp; Onur N Karayal; Joseph R Calabrese; Gary S Sachs; Elizabeth Pappadopulos; Kathleen S Ice; Cynthia O Siu; Eduard Vieta Journal: Eur Neuropsychopharmacol Date: 2011-07-28 Impact factor: 4.600